Design of effective immunotherapy for human autoimmunity Design of effective immunotherapy for human autoimmunity2018-01-17T17:03:46-05:00
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses2018-01-17T17:03:38-05:00
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis2018-01-17T17:03:38-05:00
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?2018-01-17T17:03:38-05:00
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis2018-01-17T17:03:31-05:00
Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study2018-01-17T17:03:31-05:00
The Janus face of CNS-directed autoimmune response: a therapeutic challenge The Janus face of CNS-directed autoimmune response: a therapeutic challenge2018-01-17T17:03:31-05:00
Drug researchers leak secrets to Wall St. Drug researchers leak secrets to Wall St.2018-01-17T17:03:31-05:00
A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS2018-01-17T17:03:31-05:00